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Recurrent Distal 7q11.23 Deletion Including HIP1
and YWHAG Identified in Patients with Intellectual
Disabilities, Epilepsy, and Neurobehavioral Problems
Melissa B. Ramocki,1,2,16 Magdalena Bartnik,3,16 Przemyslaw Szafranski,4,16 Katarzyna E. Ko1odziejska,4
Zhilian Xia,4 Jaclyn Bravo,4 G. Steve Miller,5,6 Diana L. Rodriguez,1,2 Charles A. Williams,7
Patricia I. Bader,8 El _zbieta Szczepanik,9 Tomasz Mazurczak,9 Dorota Antczak-Marach,9
James G. Coldwell,5 Cigdem I. Akman,1,2 Karen McAlmon,10,11,12 Melinda P. Cohen,13
James McGrath,14 Elizabeth Roeder,15 Jennifer Mueller,7 Sung-Hae L. Kang,4 Carlos A. Bacino,4
Ankita Patel,4 Ewa Bocian,3 Chad A. Shaw,4 Sau Wai Cheung,4 Tadeusz Mazurczak,3
and Pawe1 Stankiewicz3,4,*
We report 26 individuals from ten unrelated families who exhibit variable expression and/or incomplete penetrance of epilepsy, learning
difficulties, intellectual disabilities, and/or neurobehavioral abnormalities as a result of a heterozygousmicrodeletion distally adjacent to
theWilliams-Beuren syndrome region on chromosome 7q11.23. In six families with a common recurrent ~1.2Mb deletion that includes
the Huntingtin-interacting protein 1 (HIP1) and tyrosine 3-monooxygenase/tryptophan 5-monooxygenase activation protein gamma
(YWHAG) genes and that is flanked by large complex low-copy repeats, we identified sites for nonallelic homologous recombination
in two patients. There were no cases of this ~1.2 Mb distal 7q11.23 deletion copy number variant identified in over 20,000 control
samples surveyed. Three individuals with smaller, nonrecurrent deletions (~180–500 kb) that include HIP1 but not YWHAG suggest
that deletion of HIP1 is sufficient to cause neurological disease. Mice with targetedmutation in theHip1 gene (Hip1/) develop a neuro-
logical phenotype characterized by failure to thrive, tremor, and gait ataxia. Overall, our data characterize a neurodevelopmental and
epilepsy syndrome that is likely caused by recurrent and nonrecurrent deletions, including HIP1. These data do not exclude the possi-
bility that YWHAG loss of function is also sufficient to cause neurological phenotypes. Based on the current knowledge of Hip1 protein
function and its proposed role in AMPA andNMDA ionotropic glutamate receptor trafficking, we believe thatHIP1 haploinsufficiency in
humans will be amenable to rational drug design for improved seizure control and cognitive and behavioral function.The vast majority (~95%) of patients withWilliams-Beuren
syndrome (WBS [MIM 194050]), a common multisystem
developmental disorder characterized by supravalvular
aortic stenosis, multiple peripheral pulmonary arterial
stenoses, elfin face, infantile hypercalcemia, and cognitive
and behavioral abnormalities, have a recurrent ~1.6 Mb
hemizygous deletion in 7q11.23.1 In a few patients with
an unusual association of WBS with infantile spasms (IS)
and more severe developmental delay or intellectual
disability (DD or ID), larger deletions extending distally
have been reported.2–7 Marshall et al.7 proposed that
deletion of the membrane-associated guanylate kinase in-
verted-2 (MAGI2 [MIM 606382]) gene, mapping ~3.5 Mb
distal to the WBS common deletion (Figure 1), causes IS,
because 15 of 16 individuals with 7q11.23-q21.1 deletions
involving MAGI2 developed IS, whereas 11 of 12 subjects
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The Americannot. Supporting this notion, Marshall et al. found that
mouse Magi2 interacts with Stargazin and that mutations
in Stargazin cause epilepsy in mice.7,8
However, to date, no point mutations have been identi-
fied inMAGI2, and although no epilepsy was documented
for the 12 subjects with 7q11.23-q21.1 deletions proximal
to MAGI2, 11 of these subjects had severe DD or ID.5,7,9,10
In addition, at least three patients withWBS, DD or ID, and
IS with 7q11.23 deletions proximal to MAGI2 have been
reported.4,11,12 Kamoike et al.12 suggested that in addition
to deletion of MAGI2, deletion of the tyrosine 3-monoox-
ygenase/tryptophan 5-monooxygenase activation protein,
gamma (YWHAG [MIM 605356]) or Huntingtin-interact-
ing protein 1 (HIP1 [MIM 601767]) genes, which are both
normally expressed in the brain, may contribute to
epilepsy and ID in these patients. To further investigate
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Figure 1. Schematic Representation of the Genomic Architecture in Distal 7q11.23
The extent of the identified deletions is shown in red, and duplications are shown in green. The NAHR sites identified in patients 6 and 8
were mapped to the directly-oriented ~25 kb subunits (orange) with crossovers within the subunits identified in two patients (6 and 8)
with recurrent deletions.knockdowns of ywhag and hip1 in zebrafish. hip1/ zebra-
fish had reduced or complete absence of yolk extension,
narrowing along the dorsoventral axis, and severe mandib-
ular aplasia, but there was no obvious effect on the devel-
oping brain. In ywhag/ zebrafish, however, increased
diameter of the heart tube and reduced brain size were
appreciated, leading Kamoike et al. to postulate that hap-
loinsufficiency of YWHAG causes the IS and cardiomegaly
phenotypes observed in their patients.12
We queried our chromosome microarray database for
individuals with distal 7q11.23 deletions or duplications
that include the HIP1 and/or YWHAG genes. Three small
nonrecurrent distal 7q11.23 deletions, six common recur-
rent distal 7q11.23 deletions, and one larger-sized dele-
tion harboring HIP1 were found in ~29,510 individuals
referred for chromosomal microarray analysis (CMA) at
the Baylor College of Medicine Medical Genetics Labora-
tories (BCM MGL), yielding a frequency of 1 in 3279,
comparable with the 1 in 2960 frequency of the 680 kb
CHRNA7 (MIM 118511) deletion.13 Our collection of
subjects referred for CMA includes mostly children with
various combinations of DD, ID, autism, and birth defects;
a small percentage has epilepsy, but rarely as an isolated
finding.
Initial array CGH analyses were performed withmicroar-
rays designed by BCM MGL and manufactured by Agilent
Technology as previously described.14,15 We received DNA
samples from all probands and their family members
after obtaining informed consent via protocols approved
by the Institutional Review Board for Human Subject
Research at Baylor College of Medicine (except patient 5,
who is deceased, and patient 6, for whom no forwarding
contact information was available). Patients’ genomic858 The American Journal of Human Genetics 87, 857–865, DecembDNAwas extracted from peripheral blood via the Puregene
DNA isolation kit (Gentra System). To fine map the size
and the extent of the genomic deletions and duplica-
tions, we performed oligonucleotide microarray CGH anal-
yses with custom-designed 7q11.23 region-specific high-
resolution oligonucleotide microarrays: 135K (NimbleGen
Systems) according to the manufacturers’ instructions.
Microarrays were scanned on the NimbleGen MS 200
scanner. Scans were processed with NimbleScan version
2.5 and analyzed with SignalMap version 1.9. Confirma-
tory and parental fluorescence in situ hybridization anal-
yses in patients and their parents were performed with
chromosome 7q11.23-specific bacterial artificial chromo-
some clones CTB-139P11, RP11-229D13, RP11-622P13,
and RP11-845K6 via standard procedures. Clinical histories
were obtained from parents and from physicians. For the
patients with epilepsy, medical records including EEG
reports were reviewed, and physicians and families were
interviewed about clinical seizure semiology, thereby
allowing us to classify the epilepsy in most cases as gener-
alized, localization related, or mixed.
Overall, we identified 26 individuals from ten unrelated
families who exhibit variable expression and/or incom-
plete penetrance of epilepsy, learning difficulties, intellec-
tual disabilities, and/or neurobehavioral abnormalities
as a result of hemizygous genomic deletions, including
HIP1. The deletions mapped between the WBS region
and MAGI2 ranged in size from ~4 Mb to ~180 kb and
included apparent recurrent, as well as nonrecurrent, rear-
rangements (Figure 2). Our subjects presented with a range
of neurological and neurodevelopmental phenotypes
(Table 1). Epilepsy was common among probands with
distal 7q11.23 deletion with 8 of 10 (80%) affected;er 10, 2010
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Figure 2. Results of Array CGH Analysis with a 7q11.23 Region-Specific High-Resolution Oligonucleotide Microarray, Including the
WBS Common Deletion Region
The extents of the identified deletions (red) and duplications (green) (135K, NimbleGen). Patients 1, 3, 6–8, and 10 had a common
~1.2 Mb deletion.however, among all family members with the deletion,
epilepsy was present in 13 of 26 (50%). Generalized
epilepsy was most common, occurring in 6 of 13 (46%);
localization-related epilepsy occurred in 4 of 13 (31%),
mixed epilepsy in 1 of 13 (8%), epilepsy not otherwise
specified in 1 of 13 (8%), and neonatal epilepsy in 1 of
13 (8%). Routine clinical brain MRI exams were typically
interpreted as normal, but one subject (patient 4) had
a dysembryoplastic neuroectodermal tumor and a temporal
lobe cortical dysplasia that were identified on pathological
examination status post epilepsy surgery (temporal lobec-
tomy) for medically refractory symptomatic localization-
related epilepsy, and a second subject (patient 3) had a
mild Chiari 1 malformation.
The intellectual spectrum associated with distal 7q11.23
deletion is broad. Of the 12 surviving children, (eight
surviving probands, including patient 10, and their four
siblings; patients 1 and 5 are deceased), 7 of 12 (58%)
had moderate to severe global DD or ID and/or were on
the autistic spectrum, 2 of 12 (17%) had mild ID, 2 of 12
(17%) were diagnosed with learning disabilities only, and
1 of 12 (8%) was developmentally on target. Of the 12
adults, 3 of 12 (25%) had mild ID and had required special
education, 3 of 12 (25%) expressed concern that they had
really struggled in school or disproportionately with
certain subjects, and 6 of 12 (50%) reported no cognitive
difficulties, no special needs in the educational system,The Americanand no history of neuropsychiatric disease. Behavioral
problems were common among children with distal
7q11.23 deletion and include inattention, hyperactivity,
impulsivity, and aggression. Depression and self-abusive
behaviors were reported in one patient. Autism was diag-
nosed in 2 of 12 children (siblings, 17%).
We have also identified two reciprocal microduplications
inclusive of HIP1 in three children from two families
(Figure 2; Table 1). Although none of these children have
developed epilepsy, 1 of 3 (33%) has an expressive
language disorder, 2 of 3 (67%) have attention deficit
hyperactivity disorder and problems with aggression, 1 of
3 (33%) was formally diagnosed with bipolar disorder,
and 1 of 3 (33%) had a large posterior encephalocele
(Chiari III malformation).
In contrast to other disease-associated recurrent deletion
and duplication CNVs that typically arise de novo (e.g.,
16p11.2 and 1q21.1),16–19 we found that our patients
inherited the common or small distal 7q11.23 deletion
or duplication in all cases for which parental origin could
be determined. Deletions of distal 7q11.23 are therefore
reminiscent of the typically inherited 15q13.3 microdele-
tions that cause epilepsy and other neurodevelopmental
phenotypes but exhibit incomplete penetrance and var-
iable expressivity.20–24 The incomplete penetrance of
epilepsy and ID in apparently clinically unaffected trans-
mitting parents can potentially be explained by a two-hitJournal of Human Genetics 87, 857–865, December 10, 2010 859
Table 1. Phenotypic Features of 26 Individuals from Ten Unrelated Families with an HIP1 Deletion and Four Individuals from Two
Unrelated Families with an HIP1 Duplication
Age at
Diagnosis Sex Ancestrya CNV
Cognitive
Function,
Other Problems Epilepsy Inheritance Method
Other CMA
Abnormalities
V8
Pt 1 1 mo. Female E Com del 34 wga, cystic
encephalomalacia,
death in neonatal
period
Neonatal
seizures
Pat V5.0, V8.0 None
Pt 1’s father 34 yr. Male E Com del Normal Generalized
epilepsy
Unknown FISH Unknown
Pt 2 4 yr. Male E/H Small del Global DD,
microcephaly,
PDA
None Mat V6.1, V8.0 Xp22.31dupb
Pt 2’s mother 30 yr. Female H Small del Normal None Unknown FISH Unknown
Pt 3 4 yr. Male E Com del Global DD, ID,
ASD, Chiari 1
Febrile seizures,
generalized
epilepsy
Mat V6.1, V8.0 None
Pt 3’s mother 45 yr. Female E Com del Struggled in
school,
miscarriages
(singleton
and twin)
None Unknown FISH Unknown
Pt 3’s sister 7 yr. Female E Com del ASD None Mat V5.0 None
Pt 4 13 yr. Female E Small del Severe ID Medically
refractory
generalized
epilepsy s/p VNS
placement
Mat V6.2, V8.0 5q31.2delc
Pt 4’s mother 38 yr. Female E Small del Difficulty
with reading
None Unknown FISH Unknown
Pt 4’s brother 14 yr. Male E Small del Severe ID,
aggressive,
hyperactive
Generalized
epilepsy
Mat V6.2 None
Pt 5 3 mo. Female H Large del WBS, congenital
heart disease
None De novo V6.2, V8.0 None
Pt 6 4 yr. Female E Com del Moderate ID,
hyperactivity
Mixed
epilepsy
Pat V6.3, V8.0 None
Pt 6’s father 27 yr. Male E Com del Learning
disabilities,
special
education
Epilepsy Unknown FISH Unknown
Pt 6’s brother 1.5 yr. Male E Com del Mild ID,
hyperactivity
None Pat V6.4 None
Pt 7 9 yr. Female AA Com del Learning
disabilities
Medically
intractable
localization-
related epilepsy
Pat V8.0 Xp11.22dupd
Pt 7’s sister 11 yr. Female AA Com del Learning
disabilities
Localization-
related epilepsy
Pat V8.1 Xp11.22dupd
Pt 7’s father 38 yr. Male AA Com del Struggled
in math
Localization-
related epilepsy
Unknown FISH Unknown
Pt 8 13 yr. Female E Com del Mild ID, ADHD,
depression,
mood disorder,
aggressive
Generalized
epilepsy
Unknown/
adopted
V8.0 None
Pt 9 3 yr. Male AA Small del Normal Localization-
related epilepsy
Mat V8.1 None
Pt 9’s mother 18 yr. Female AA Small del Normal None Pat FISH Unknown
Pt 9’s MGF 38 yr. Male AA Small del Normal Single seizure
event as adult
Unknown FISH Unknown
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Table 1. Continued
Age at
Diagnosis Sex Ancestrya CNV
Cognitive
Function,
Other Problems Epilepsy Inheritance Method
Other CMA
Abnormalities
V8
Pt 10 19 yr. Male E Com del Severe/
moderate ID
Generalized
epilepsy
Mat V8.0 None
Pt 10’s mother 40 yr. Female E Com del Mild ID, special
education
None Mat FISH Unknown
Pt 10’s MGM 70 yr. Female E Com del Normal None Unknown FISH Unknown
Pt 10’s uncle 30 yr. Male E Com del Mild ID, special
education
None Mat FISH Unknown
Pt 10’s aunt 41 yr. Female E Com del Mild ID None Mat FISH Unknown
Pt 11 3 mo. Male E Small dup Large posterior
encephalocele/
Chiari III
malformation,
hydrocephalus VPS
None Pat V8.0 None
Pt 11’s father 34 yr. Male E Small dup Spinal cord
schwannoma
None Unknown FISH Unknown
Pt 12 16 yr. Male E Com dup Behavior/mood
disorder (diagnosed
with bipolar
disorder),
ADHD, aggressive
None Not mate V8.0 None
Pt 12’s sister 5 yr. Female E Com dup Speech delay,
ADHD,
aggressive
None Not mate FISH, V8.1 11p14.3p14.2delf
The following abbreviations are used: ADHD, attention deficit hyperactivity disorder; ASD, autism spectrum disorder; com, common; del, deletion; dup, dupli-
cation; FISH, fluorescence in situ hybridization; mat, maternal; MGF, maternal grandfather; MGM, maternal grandmother; mo., months old; pat, paternal; PDA,
patent ductus arteriosus; pt, patient; s/p, status post; V, version; VNS, vagus nerve stimulator; yr., years old; VPS, ventriculoperitoneal shunt; wga, weeks of gesta-
tional age.
a AA, African American; E, European; H, Hispanic.
b arrXp22.31(6876449-8075153)x2.
c arr5q31.2(138439046- 138591992)x1.
d arrXp11.22(53081560-53332267)x3.
e Father in prison.
f arr11p14.3p14.2(25518340-26613145)x1. (Coordinates according to NCBI build 36, March 2006.)model,25,26 single nucleotide variants of the second
allele,27 or a combination thereof. The observed increase
in severity of phenotypes among probands is likely ex-
plained by ascertainment bias.
We did not study a matched control set of healthy
children, but we performed two analyses to consider
the frequency of the common recurrent ~1.2 Mb distal
7q11.23 deletion in normal controls from the studies
that surveyed CNV incidence. We did not find this dele-
tion in approximately 20,000 individuals from different
world populations28–34 (dbGaP; M. Hurles, personal com-
munication). To further refine our analysis, we calculated
a p value for the HIP1 deletion event among patients
with an indication of epilepsy on their submitting diag-
nosis. Of the ten distinct families with the HIP1 deletion,
eight had epilepsy as an indication and two did not. In our
CMA database as a whole, ~5,000 patients have epilepsy as
an indication, whereas ~24,500 do not. Together, these
values suggest that the incidence of epilepsy as an indica-
tion is significantly higher in the HIP1 deletion subjects,
with a Fisher’s exact p value of 2.224 3 105 and a 95%
confidence interval of between 3.91 and 189.12.The AmericanThree smaller-sized overlapping deletions (~180–500 kb)
in patients 2, 4, and 9 (Figure 2) enabled us to narrow
the critical region to a single gene,HIP1 encoding Hunting-
tin-interacting protein 1,35 that has a role in clathrin-
mediated endocytosis.36,37 HIP1 has been implicated in
the pathogenesis of Huntington disease (MIM 143100)38
and prostate and colon cancers.39 A balanced reciprocal
translocation t(5;7)(q33;q11.2) resulting in a HIP1 and
platelet-derived growth factor b receptor (PDGFbR [MIM
173410]) fusion protein was identified in a patient with
chronic myelomonocytic leukemia.40
Hip1/ mice developed premature testicular degenera-
tion, severe spinal deformities, abnormal hematopoiesis,
and cataracts.41,42 Reportedly, these animals had no gross
structural abnormalities of the central nervous system;
however, both Hip1/ and Hip1þ/ mice develop epilepsy
(T. Ross, personal communication). In a second loss-of-
function model, Metzler et al.43 showed that by 3 months
of age, Hip1/ mice develop neurological problems
characterized by failure to thrive, tremor, and gait ataxia
(likely secondary to a rigid thoracolumbar kyphosis).
Hip1/ mice have defects in presynaptic function, asJournal of Human Genetics 87, 857–865, December 10, 2010 861
demonstrated by a reduction in paired-pulse facilitation in
hippocampal brain slices. In addition, Hip1/ mice
demonstrate delayed recovery from chemically induced
long-term depression, as well as altered a-amino-3-
hydroxy-5-methyl-4-isoxazolepropionic acid (AMPA) and
N-methyl-D-aspartate (NMDA) receptor function.43,44
Hip1 colocalizes in hippocampal and cortical neurons
with NMDA ionotropic glutamate receptors (iGluRs), and
Hip1/ mice have a profound decrease in NMDA-induced
AMPA-type iGluR clathrin-mediated internalization.38,43
Endocytic trafficking and recycling maintains a pool of
mobile surface AMPA receptors required for synaptic
potentiation.45 Interestingly, the increased internalization
of ionotropic receptors for glutamate has been demon-
strated to be pathogenic in mouse and Drosophila models
of Fragile X syndrome (MIM 300624).46 Mutations in the
ionotropic glutamate receptor 3 gene (GRIA3 [MIM
305915]) have been found in patients with X-linked
mental retardation, seizures, and autistic behavior
(MRX94 [MIM 300699]).47 Moreover, AMPA receptors
have also been implicated in patients with clinical diag-
noses of schizophrenia (MIM 181500), Alzheimer disease
(MIM 104300), amyotrophic lateral sclerosis (MIM
105400), stroke, Parkinson disease (MIM 168600), depres-
sion, epilepsy, and Rasmussen encephalitis.48
Given that in six families the common recurrent ~1.2Mb
deletions are flanked by large complex low-copy repeats
(HIP1-LCRs), we hypothesized that they have likely arisen
via nonallelic homologous recombination (NAHR). To
address this hypothesis, we performed computational anal-
yses of the proximal and distal HIP1-LCR copies. We found
that they are organized as clusters of subunits, two of which
are in direct orientation (Figure 1). Long-range PCR primers
were designed to be specific to regions directlyflanking each
of these two paralogous subunit pairs in both HIP1-LCR
copies and to each subunit (when possible) in order to
amplify the predicted junction between the proximal and
distal subunits (orange) of HIP1-LCRs. Amplification of
the 4–17 kb fragments was performed with Takara LA Taq
polymerase (TaKaRa Bio USA) following the manufacturer’s
protocol. Amplification of theGC-rich region inHIP1-LCRs
wasdone in thepresenceof 4%dimethyl sulfoxide,with the
following conditions: 94C for 1 min 30 s, 61C for 30 s,
72C for 6 min. PCR products were treated with ExoSAP-IT
(USB) to remove unconsumed dNTPs and primers and
were directly sequenced by Sanger method with the initial
primers and primers specific for both paralogous subunits
in the proximal and distal copies of the HIP1-LCRs (Lone
Star Labs). The genomic sequences based on the oligonucle-
otide coordinates from the array CGH experiments were
downloaded from the UCSC Genome Browser (NCBI build
37, February 2009) and assembledwith Sequencher version
4.2 software (Gene Codes). Interspersed repeat sequences
were identified with RepeatMasker). DNA GC content was
analyzed with CPGPlot. Using long-range PCR primers F:
50-CTCTATGGAGCACAGATTCCATGCTAGACC, specific
to the region centromeric and adjacent to the ~25 kb862 The American Journal of Human Genetics 87, 857–865, Decembsubunit in the proximal HIP1-LCR copy, and R: 50-AGATCA
GAGATCCTCTATTTTCCCCCTTAATC, specific to both
subunits, we identified NAHR sites in patients 6 and 8
between the cis-morphic nucleotides or paralogous
sequence variants in a 368 bp GC-rich interval (hg19; chr.
7:75,071,539-75,071,906; chr. 7:76,256,141-76,256,508 in
theproximal anddistalHIP1-LCRs, respectively; Figure 3).49
These collective data suggest that haploinsufficiency of
HIP1 is sufficient to alter neuronal homeostasis in a manner
that predisposes the human brain to both focal and general-
izedepilepsies, aswell as toabroad rangeofcognitivedysfunc-
tion and neurobehavioral abnormalities, including mild to
severe intellectual disabilities and inattention, hyperactivity,
impulsivity, and aggression through a mechanism involving
abnormal AMPA and NMDA iGluR trafficking. However,
these data do not exclude haploinsufficiency of YWHAG as
a contributing factor to the neurological phenotypes in
patients with deletions of both HIP1 and YWHAG, nor do
they exclude YWHAG as a candidate gene that, when altered,
is also sufficient to cause neurological dysfunction.
Future studies should include sequence analysis of both
the HIP1 and YWHAG genes in patients with unexplained
epilepsy and neurodevelopmental or neurobehavioral
syndromes, natural history protocols to document the
full spectrum of human phenotypes associated with HIP1
and/or YWHAG loss or gain of function, complete neuro-
logical and neurobehavioral characterization of Hip1 and
Ywhag function in mice, and preclinical drug studies in
these mouse models.Acknowledgments
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